newsfilter
← Latest News
Earnings Call Transcripts·

INOVIO PHARMACEUTICALS, INC. - Jefferies Global Healthcare Conference in London - INOVIO PHARMACEUTICALS INC

Good evening. I now have the pleasure to introduce you to Jacqueline Shea from Inovio Pharmaceuticals. Good afternoon and thank you very much to Jefferies for the opportunity to present today, to tell you about some of the exciting work that we're doing at Inovio and about the approval of Viseric, our first product, recently approved by FDA. So to kick off, to give you a quick overview of our company, this is just our standard-looking disclaimer slide. During this presentation, I'll be making some forward-looking statements. So to give You a quick Overview of the Company, we're a company that's focused on commercializing and developing dna medicines to help treat and prevent hpv related diseases cancer and infectious diseases our lead product for cerek was recently approved by fda under the accelerated approval program for the treatment of recurrent respiratory papillomatosis or rrp that's a rare hpv-related disease of the respiratory tract. With Viseric, we have a patient-centric treatment regimen with what we believe is the potential to become the preferred first-line immunotherapy treatment for RRP. Very importantly, Viserc generates an immune response that targets the root cause of RRP, the virus that causes RRP, so it targets HPV 6 and 11. We were approved on October 30th. We expect to be able to ship product within 60 days of approval, and we'll have our full field force deployed in the first quarter of next year. We're working with Sineos Health in terms of our field deployment partner. And this is the first product approved from this platform, So it's really a validation of our technology. Following on behind for CEREC, we have a deep clinical pipeline with multiple near and mid-term catalysts. And our current cash, cash equivalents, et cetera, will take us through to the end of fourth quarter next year without any further fundraising or revenue. And importantly, we Have No Debt on the balance sheet. so to tell you about dna medicines and how they work as this is a new platform we start off by identifying the gene sequence of the protein that we want to produce in the body we then use our proprietary algorithms to optimize that gene sequence for expression within the body we insert it into a circular molecule of dna called a plasmid and we can manufacture these plasmids at high volume using typical biotechnology manufacturing processes. We deliver our DNA plasmid to the body using our proprietary delivery devices called Selectra. Selectra uses very brief electrical pulses to open pores in the cell membrane to allow the DNA plasmids to enter. Once the DNA plasmods are in the cell, they provide the instructions to make proteins, and these proteins can be used to drive an immune response, as in the case of Viseric, or the proteins themselves can be the therapeutic agent. So we can encode monoclonal antibodies or other proteins and have the cells secrete these proteins into the circulation. So as you can see, this is a very versatile platform with a lot of potential across multiple disease areas. So moving on then to Viseric, our recently approved first product. Viserc has received a very broad indication. It's approved to reduce the frequency of surgery in adults with RRP, and we received an accelerated approval from FDA. Voseric is regulated as a combination product in the U.S. So the drug component was approved in combination with our delivery device, the Selectra 5-PSP. And the drug components of the CEREC consists of two DNA plasmids. One encodes for proteins or antigens from the HPV virus that causes RRP. And the other encodes the human IL-12, which acts as an immune adjuvant to enhance the immune response. so as we transition to becoming a commercial stage company clearly our focus and emphasis is on maximizing the viseric opportunity clearly our next objective is to execute a successful commercial launch and then to move on given this platform validation to utilize this to really maximize the value of the pipeline through forming additional partnerships. So to tell you a bit more about recurrent respiratory papillomatosis and why Viseric really targets the root cause of RRP. So it's a rare disease. It's characterized by these small wart-like growths called papillomas in the respiratory tract that are driven by HPV of HPV infection. And to date, repeated surgery has been the standard of care. So either lasers or scalpel, cold steel, to remove the papillomas from the larynx and the vocal cords. And the vocal cords are incredibly delicate structures. They don't regenerate. They have to vibrate thousands of times a second for you to be able to talk. So as I'm sure you can imagine, repeated surgery and scarring to these very delicate structures can very rapidly permanently damage your ability to talk. RRP can also impact your ability, in addition to impacting your ability to talk, it can impact yourability to swallow, to breathe, and in some cases RRP can spread to the lungs where it can become malignant and in those cases the outcomes are normally pretty poor. So as you can see this is really a very debilitating disease and some of these patients have had hundreds of surgeries over their lifetime and every surgery comes with both a risk, the risk of irreversible damage and a cost to the patient. The cost in terms of impact to quality of life, recovery, medical costs, loss of work, socializing, etc. So it's a really debilitating disease. And what Viseric does is Viserc drives a targeted immune response that targets HPV-infected cells and eliminates them. And that slows or prevents the growth of papilloma. So this gives you a quick overview of the clinical trial that generated the data that led to our approval. So we have orphan drug designation in the US, we had breakthrough therapy designation, we also have orphaned drug designation within the EU, and ILAP designation within the UK. And in this phase 1-2 trial, a few things I want to point out to you. We gave four doses of a CEREC over a nine-week period. We enrolled patients who had had two or more surgeries in the prior year. And very importantly, in our study design, we didn't require any minimal residual disease surgeries, so any scoping or surgeries during the dosing window. And then we counted every surgery after treatment towards our efficacy endpoint. And as a phase 1-2 trial, clearly as well, we focused on safety. We also conducted a retrospective trial where we looked back and collected data for year 2 and year 3 from the same patients who'd participated in the first trial. And this is what we saw. So in the first year, we saw 72% of patients show a 50% to 100% reduction in surgeries compared to the year prior to treatment. And we saw 28% of patience require no surgeries at all in the 12 months following treatment. And 50% of those patients in year two then exhibited a complete response, so required no surgeries in year three. So what we're seeing is very good efficacy in year one, which then deepens into year two. So 86% of patients had a 50% to 100% reduction in year two, 50% of them required no surgery. And we see this in combination with a very tolerable safety profile. We don't require surgeries to maintain minimal residual disease during the dosing window, which is very important because it minimizes patients' exposure to surgeries. And what patients are really focused on, what matters most to them, is avoiding these surgeries. And it was also very well tolerated with a very low rate of systemic adverse events. When we look at our mechanism of action, this is the first product approved from this platform, which we're extremely proud of. And so we have a different mechanism of action to other platforms out there. We're driving an immune response in a different way. We're also driving animmune response against different antigens. And very importantly, we're not impacted by the immunosuppressive papilloma microenvironment. So our other therapists have reported that they are impacted by this papillomum microenvironments, and Viseric is not impacted. So our complete clinical data has been published in Nature Communications and also in the Laryngoscope, which is the journal most commonly read by otolaryngologists who are the specialists who treat RRP. So when it came to our accelerated approval, FDA chose a novel endpoint. So they chose to look at complete response in patients who had had three or more surgeries in the year prior to treatment. And then they looked at 12 months following completion of treatment as the efficacy analysis for the accelerated approval. So we saw a median of 4.5 surgeries in the year prior to treatment in this 3-plus population. So this is really a very severe population with RRP. Importantly, we don't require surgeries during the dosing window as part of our treatment regimen. And in this analysis, we showed that 27% of patients required no surgeries in the year following treatment, which would not be expected from the natural course of the disease. So a really significant effect. So how do we see the market opportunity for Viseric? While it's a rare disease, it's not that rare, we estimate from claims database analysis that there are approximately 25,000 patients with active RRP in the U.S. Most patients are still managed surgically, and as I've mentioned, every surgery comes with that risk and a cost to the patient. There is a recently approved immunotherapy to treat RRP. However, and there has also been a recent position paper put out by the RRPF, or the Recurrent Respiratory Papillomatosis Foundation, which is the patient advocacy organization, in conjunction with key opinion leaders in the field, that recommends immunotherapy as first-line therapy for RRP, and Viseric as an immunotherapy is also recommended as first-line therapy. To date, only a fraction of the prevalent population of RRP patients in the U.S. have been treated with immunotherapy, so the vast majority of the market opportunity remains for Viseric. We believe, based on Viserics product profile, that it has the potential to become the preferred first- line therapy in this space. As I mentioned, it's targeting the root cause of the disease. It's not just like surgery where you're not eradicating or attacking the virus. It is a very patient-centric approach to treatment because it is not requiring additional surgeries during the dosing window. It has a very favorable tolerability profile, which really minimizes disruptions to patients' lives. It also has a simple administration process, which is easy for health care providers to use, only requires standard refrigeration, has a three-year shelf life, and this flexibility allows administration in the doctor's office. So when you think about where RRP patients are treated, physicians don't have to refer out their patients to other centers to receive immunotherapy with Fiseric. So, when we think about the patient journey, as I've mentioned, it's very important to intervene early in the disease course because the surgery that causes permanent damage to the vocal cords could occur at any point. So after an initial diagnosis, the KOL recommendation is to start immunotherapy as soon as possible. So, after the patient and the treating physician together decided to use Viseric, the very next surgery that's required to treat the papilloma or to remove the papilla can be the surgery that initiates treatment with viseric. And then there are four doses over nine weeks that are required. And as I mentioned, we have a broad indication for reduction of surgery in adults with RRP. So when we think about what constitutes a successful launch for us, it's about establishing broad access and we have an objective to have policies in place from payers and insurers that cover 80% of patients within nine months of approval. We're also looking to really drive awareness and adoption for Viseric and of course we want to provide seamless customer support as well as to our patients. We want to make the process as easy as possible for both physician and patient. When we think about the physicians who treat RRP, this is really a very targeted and concentrated market. About 400 laryngologists in the U.S. treat the vast majority of RRP patients, and these are largely split across integrated delivery networks or IDNs. About 80% of patients are treated in that setting, and about 20% of patients are in the community setting. When we look at the mix of commercial versus Medicare, about 70% of RRP patients are commercially insured. We're working to put a field force in place that should cover approximately 90% of RLP patient potential. We believe we've established the right infrastructure in place to support demand for the first year of launch and beyond. We have established a manufacturing network with CMOs who manufacture the plasmic components of Viseric, and then we manufacture the device in-house ourselves. And we believe we have got the potential for commercial success based on the strength of our clinical data and the product profile of Viseric, our broad adult indication, the significant unmet need that's out there with these patients desperate to avoid surgery, and a very concentrated prescriber base. So as we think about Viserc, we're also thinking about how we maximize the opportunity. And for Viserac, that includes additional treatment strategies. Our initial treatment regimen of four doses delivered impressive efficacy, but RRP is a chronic life-threatening disease, and we believe additional doses or continued treatment may provide additional clinical benefit to patients by either keeping them in response or improving their clinical response that they're seeing. So we're going to be looking at continued treatment as part of our development of Viseric. There's also the potential to expand into pediatrics and also geographical expansion. So we recently announced today, I believe, that we've submitted our conditional marketing authorization application to EMA. So we also see potential for expansion in international markets. so as we think about our pipeline in our near term our focus is really about the commercialization of viseric in the midterm it's about advancing our diversified clinical pipeline so following on behind viserick we have other candidates such as 3112 which is targeting hp for hpb positive head neck cancer, and also 5412, which is targeting neoplastoma, one of the most common and deadly brain cancers. And both of these candidates have a similar mechanism of action to Viseric, so they're driving T-cell responses. And we also have some earlier stage candidates, which are really based on treating protein replacement diseases. So we have preclinical programs in hemophilia A, Fabry disease, and hyperphosphatasia. And we're seeking partnerships to advance those candidates. So as you can see, there's a lot of potential across this very versatile platform. So to summarize, our first product, Viseric, is now approved by FDA under the Accelerated Approval Program in the US. And with this approval, we've made the transition to becoming a commercial stage company. We believe that CEREC has the potential to become the preferred first-line treatment option based on its compelling efficacy, a patient-centric treatment regimen, and a favorable tolerability profile combined with ease of use for the physician. In the near-term catalysts, we see coming up the launch of CERIC and also our first revenue generation, which are going to be very important catalysts for us. And we also see with this first approval of Viseric in combination with our delivery device, Selectra 5 PSP, validation of our DNA medicines platform with multiple pipeline drivers following on behind Viserica. So with that, I'll wrap up. And thank you again for your time and attention and your interest in InnoView. Thank you and good evening. Thank you. Thank you.

Company
INOVIO PHARMACEUTICALS INC
Keywords
INOVIO PHARMACEUTICALS INC